Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Payables (2016 - 2026)

Champions Oncology has reported Payables over the past 16 years, most recently at $5.7 million for Q1 2026.

  • For Q1 2026, Payables rose 12.43% year-over-year to $5.7 million; the TTM value through Jan 2026 reached $5.7 million, up 12.43%, while the annual FY2025 figure was $4.2 million, 26.76% down from the prior year.
  • Payables for Q1 2026 was $5.7 million at Champions Oncology, down from $6.0 million in the prior quarter.
  • Over five years, Payables peaked at $6.0 million in Q4 2025 and troughed at $2.5 million in Q3 2022.
  • A 5-year average of $4.7 million and a median of $4.8 million in 2025 define the central range for Payables.
  • Biggest five-year swings in Payables: soared 127.0% in 2023 and later decreased 26.76% in 2025.
  • Year by year, Payables stood at $4.6 million in 2022, then decreased by 1.5% to $4.5 million in 2023, then grew by 7.01% to $4.9 million in 2024, then increased by 23.47% to $6.0 million in 2025, then dropped by 4.46% to $5.7 million in 2026.
  • Business Quant data shows Payables for CSBR at $5.7 million in Q1 2026, $6.0 million in Q4 2025, and $4.8 million in Q3 2025.